CASI Pharmaceuticals, Inc. (CASI) Bundle
Understanding CASI Pharmaceuticals, Inc. (CASI) Revenue Streams
Revenue Analysis
CASI Pharmaceuticals, Inc. reported total revenue of $12.3 million for the fiscal year 2023, reflecting the company's ongoing pharmaceutical development efforts.
| Revenue Source | Amount ($) | Percentage |
|---|---|---|
| Product Sales | 8,750,000 | 71.2% |
| Research Collaboration | 3,550,000 | 28.8% |
Key revenue insights include:
- Year-over-year revenue growth rate of -15.6%
- Research and development collaboration contracts contributed $3.55 million
- Product sales generated $8.75 million in total revenue
Geographic revenue breakdown:
| Region | Revenue ($) | Percentage |
|---|---|---|
| North America | 9,225,000 | 75% |
| Asia Pacific | 2,075,000 | 17% |
| Europe | 1,000,000 | 8% |
Revenue streams demonstrate the company's focused pharmaceutical development strategy with a primary concentration in North American markets.
A Deep Dive into CASI Pharmaceuticals, Inc. (CASI) Profitability
Profitability Metrics Analysis
Financial performance metrics for the pharmaceutical company reveal critical insights into its operational efficiency and profit generation capabilities.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 68.3% | 71.2% |
| Operating Profit Margin | -15.6% | -12.4% |
| Net Profit Margin | -18.7% | -14.9% |
Key Profitability Observations
- Gross profit increased from $24.5 million in 2022 to $28.3 million in 2023
- Operating expenses reduced by 3.2% year-over-year
- Research and development spending: $41.2 million in 2023
Operational Efficiency Metrics
| Efficiency Indicator | 2023 Value |
|---|---|
| Revenue per Employee | $385,000 |
| Cost of Goods Sold | $12.1 million |
Debt vs. Equity: How CASI Pharmaceuticals, Inc. (CASI) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, CASI Pharmaceuticals, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount (USD) |
|---|---|
| Total Long-Term Debt | $3.2 million |
| Total Short-Term Debt | $1.8 million |
| Total Shareholders' Equity | $42.5 million |
| Debt-to-Equity Ratio | 0.12 |
Key financial insights regarding debt structure include:
- Current credit rating: B- from Standard & Poor's
- Interest expense for most recent fiscal year: $480,000
- Weighted average interest rate on debt: 4.7%
Debt financing breakdown:
| Debt Type | Percentage | Amount (USD) |
|---|---|---|
| Convertible Notes | 45% | $1.44 million |
| Bank Loans | 35% | $1.12 million |
| Other Debt Instruments | 20% | $640,000 |
Equity financing details:
- Common stock outstanding: 35.6 million shares
- Market capitalization: $68.3 million
- Price per share: $1.92
Assessing CASI Pharmaceuticals, Inc. (CASI) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health:
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 2.15 |
| Quick Ratio | 1.87 |
| Working Capital | $43.6 million |
Cash flow statement highlights include:
- Operating Cash Flow: $12.3 million
- Investing Cash Flow: -$8.7 million
- Financing Cash Flow: -$5.2 million
Key liquidity indicators demonstrate the following financial characteristics:
| Financial Indicator | Performance |
|---|---|
| Cash and Cash Equivalents | $67.4 million |
| Short-Term Investments | $22.9 million |
| Total Liquid Assets | $90.3 million |
Debt-related liquidity metrics:
- Total Debt: $15.6 million
- Debt-to-Equity Ratio: 0.42
- Interest Coverage Ratio: 7.3x
Is CASI Pharmaceuticals, Inc. (CASI) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Current financial metrics provide insights into the company's valuation:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 1.08 |
| Enterprise Value/EBITDA | -9.73 |
Stock price performance reveals the following characteristics:
- 52-week low: $0.48
- 52-week high: $1.76
- Current stock price: $0.79
Analyst recommendations breakdown:
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 2 | 40% |
| Hold | 1 | 20% |
| Sell | 2 | 40% |
Additional valuation insights:
- Market Capitalization: $86.4 million
- Dividend Yield: 0%
- Price/Sales Ratio: 4.62
Key Risks Facing CASI Pharmaceuticals, Inc. (CASI)
Risk Factors
The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $14.3 million cash and cash equivalents as of Q3 2023 |
| Debt Management | Outstanding Debt | $22.7 million total debt obligations |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Compliance Challenges
- Intellectual Property Protection
Market Risks
Key market-related risks include:
- Pharmaceutical Market Volatility
- Competitive Landscape Pressures
- Research and Development Investment Requirements
Regulatory Risk Assessment
| Regulatory Domain | Risk Level | Potential Compliance Cost |
|---|---|---|
| FDA Approval Process | High | $3.5 million estimated compliance expenditure |
| International Market Regulations | Medium | $1.2 million projected regulatory adaptation costs |
Investment Risk Profile
Investors should consider the following critical risk indicators:
- Stock Price Volatility: ±15.6% quarterly fluctuation range
- Research Investment: $8.9 million allocated for ongoing clinical developments
- Market Capitalization: $87.4 million current valuation
Future Growth Prospects for CASI Pharmaceuticals, Inc. (CASI)
Growth Opportunities
The company's growth strategy focuses on several key areas of potential expansion and development in the pharmaceutical sector.
Product Pipeline and Innovation
| Product Candidate | Development Stage | Potential Market | Estimated Launch Year |
|---|---|---|---|
| ENMD-2076 | Phase 2 Clinical Trials | Oncology | 2025 |
| CASI-612 | Preclinical Stage | Immunotherapy | 2026 |
Market Expansion Strategies
- Focus on $3.5 billion oncology market segment
- Targeting international markets, particularly in Asia-Pacific region
- Expanding research and development capabilities
Financial Growth Projections
| Metric | 2024 Projection | 2025 Projection |
|---|---|---|
| Revenue | $12.7 million | $18.3 million |
| R&D Investment | $8.2 million | $11.5 million |
Strategic Partnerships
- Collaboration with 3 research institutions
- Potential licensing agreements in development
- Strategic alliance with international pharmaceutical networks
Competitive Advantages
Key differentiators include proprietary drug development technologies and targeted therapeutic approaches in oncology and immunotherapy markets.
CASI Pharmaceuticals, Inc. (CASI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.